Contributions
Abstract: 212
Type: Oral
The not-for-profit MSBase Foundation has been operating since 2004. It is a very successful collaborative, prospective international Multiple Sclerosis registry with >39,000 patient records from >200 collaborating MS centres, >210,000 years of cumulative follow-up and a median visit density of 5 months. The MSBase data collection system, iMed, provides a graphical interface useful for day-to-day patient management. Data ownership rests with contributing centres, and democratic data sharing is the guiding principle. MSBase hosts numerous prospective substudies, including the largest incident cohort study, MSBasis, and national and regional registries for Turkey, The Middle East, Australia, and Malaysia. MSBase powers demographic studies, analysis of comparative and long-term treatment efficacy, treatment sequencing outcomes and drug safety studies. Among more than 30 peer-reviewed papers in the last 5 years utilising MSBase data, highlights include analyses of latitudinal variation in MS. Findings include that seasonal variation of relapse incidence is influenced by latitude, that the proportion of MS patients with positive oligoclonal banding in the CSF is latitudinal, and that the increase in female/male sex ratio is strongly latitudinal. MSBase has also conducted numerous comparative treatment analyses using propensity-matching procedures in lieu of randomization. Recent publications have demonstrated the superiority of either natalizumab or fingolimod over interferon-beta or glatiramer as a switching choice after on -treatment relapse of natalizumab over fingolimod in the same treatment failure switch scenario. Long-term outcome modeling in MS is a current and future focus, with a key aim of integrating serial MRI brain volume and lesion burden measures, simple cognitive monitoring tools, selected patient-reported outcomes, drug response prediction, and globally standardized drug safety cohort studies, including pregnancy exposures. A collaboration termed "BigMS”, for project-based data sharing between the largest MS Registries in the world is another exciting development, strongly supported by MSBase.
Disclosure: Helmut Butzkueven has received travel support from Merck, Biogen and Novartis and received honoraria for lectures and steering committee activities from Novartis, Biogen, Oxford Pharmagenesis, Medscape, Merck, Teva and Genzyme. The MSBase Foundation has received sponsorship from Merck, Biogen, Novartis, Genzyme, Roche and Teva.
Abstract: 212
Type: Oral
The not-for-profit MSBase Foundation has been operating since 2004. It is a very successful collaborative, prospective international Multiple Sclerosis registry with >39,000 patient records from >200 collaborating MS centres, >210,000 years of cumulative follow-up and a median visit density of 5 months. The MSBase data collection system, iMed, provides a graphical interface useful for day-to-day patient management. Data ownership rests with contributing centres, and democratic data sharing is the guiding principle. MSBase hosts numerous prospective substudies, including the largest incident cohort study, MSBasis, and national and regional registries for Turkey, The Middle East, Australia, and Malaysia. MSBase powers demographic studies, analysis of comparative and long-term treatment efficacy, treatment sequencing outcomes and drug safety studies. Among more than 30 peer-reviewed papers in the last 5 years utilising MSBase data, highlights include analyses of latitudinal variation in MS. Findings include that seasonal variation of relapse incidence is influenced by latitude, that the proportion of MS patients with positive oligoclonal banding in the CSF is latitudinal, and that the increase in female/male sex ratio is strongly latitudinal. MSBase has also conducted numerous comparative treatment analyses using propensity-matching procedures in lieu of randomization. Recent publications have demonstrated the superiority of either natalizumab or fingolimod over interferon-beta or glatiramer as a switching choice after on -treatment relapse of natalizumab over fingolimod in the same treatment failure switch scenario. Long-term outcome modeling in MS is a current and future focus, with a key aim of integrating serial MRI brain volume and lesion burden measures, simple cognitive monitoring tools, selected patient-reported outcomes, drug response prediction, and globally standardized drug safety cohort studies, including pregnancy exposures. A collaboration termed "BigMS”, for project-based data sharing between the largest MS Registries in the world is another exciting development, strongly supported by MSBase.
Disclosure: Helmut Butzkueven has received travel support from Merck, Biogen and Novartis and received honoraria for lectures and steering committee activities from Novartis, Biogen, Oxford Pharmagenesis, Medscape, Merck, Teva and Genzyme. The MSBase Foundation has received sponsorship from Merck, Biogen, Novartis, Genzyme, Roche and Teva.